Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:

Thursday, February 9, 2017

Allergy drugs may hurt your brain, study shows

Be careful out there.

Allergy drugs may hurt your brain, study shows

Benadryl, Demerol, Dimetapp, Dramamine, Paxil among drugs that were studied
Use of this class of drugs was associated with cognitive impairment and dementia

Read more here:

The research this points to;
Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults
The use of anticholinergic (AC) medication is linked to cognitive impairment
and an increased risk of dementia. To our knowledge, this is the first study to investigate the
association between AC medication use and neuroimaging biomarkers of brain metabolism
and atrophy as a proxy for understanding the underlying biology of the clinical effects of AC
To assess the association between AC medication use and cognition, glucose metabolism, and brain atrophy in cognitively normal older adults from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Indiana Memory and Aging Study (IMAS).
The ADNI and IMAS are longitudinal studies with cognitive, neuroimaging, and other data collected at regular intervals in clinical and academic research settings. For the participants in the ADNI, visits are repeated 3, 6, and 12 months after the baseline visit and then annually. For the participants in the IMAS, visits are repeated every 18 months after the baseline visit (402 cognitively normal older adults in the ADNI and 49 cognitively normal older adults in the IMAS were included in the present analysis).
Participants were either taking (hereafter referred to as the AC+participants [52 from the
ADNI and 8 from the IMAS]) or not taking (hereafter referred to as the AC−participants [350
from the ADNI and 41 from the IMAS]) at least 1 medication with medium or high AC activity.
Data analysis for this study was performed in November 2015.
Cognitive scores, mean fludeoxyglucose F 18 standardized uptake value ratio (participants from the ADNI only), and brain atrophy measures from structural magnetic resonance imaging were compared between AC+participants and AC−participants after adjusting for potential confounders. The total AC burden score was calculated and was related to target measures. The association of AC use and longitudinal clinical decline (mean [SD] follow-up period, 32.1 [24.7] months [range, 6-108 months]) was
examined using Cox regression.
The52AC+participants (mean [SD] age, 73.3 [6.6] years) from the ADNI showed
lower mean scores on Weschler Memory Scale–Revised Logical Memory Immediate Recall
(raw mean scores: 13.27 for AC+participants and 14.16 for AC−participants; P= .04) and the
Trail Making Test Part B (raw mean scores: 97.85 seconds for AC+participants and 82.61
seconds for AC−participants; P= .04) and a lower executive function composite score (raw
mean scores: 0.58 for AC+participants and 0.78 for AC−participants; P= .04) than the
350 AC−participants (mean [SD] age, 73.3 [5.8] years) from the ADNI. Reduced total cortical
volume and temporal lobe cortical thickness and greater lateral ventricle and inferior lateral
ventricle volumes were seen in the AC+participants relative to the AC−participants.
The use of AC medication was associated with increased brain atrophy and dysfunction and clinical decline. Thus, use of AC medication among older adults should likely be discouraged if alternative therapies are available.
JAMA Neurol
. doi:10.1001/jamaneurol.2016.080

No comments:

Post a Comment